Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1659+0.0039 (+2.41%)
At close: 04:00PM EST
0.1664 +0.00 (+0.30%)
After hours: 07:42PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.1620
Open0.1649
Bid0.1620 x 1100
Ask0.1663 x 4000
Day's Range0.1619 - 0.1664
52 Week Range0.1400 - 1.4300
Volume753,710
Avg. Volume507,665
Market Cap6.405M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-2.4370
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for WINT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Windtree Therapeutics, Inc.
    Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 3Q22. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings (among others) in order to determine their core holdings and new purchases. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of Activist investors, according to Vickers.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

    WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate. Pursuant to the Inducement Offer Letters, the Company agreed to red

  • GlobeNewswire

    Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

    WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), following the expiration of

  • Zacks

    Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why

    Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Advertisement
Advertisement